펄스 필드 절제 시장 기회, 성장 촉진요인, 산업 동향 분석, 예측(2025-2034년)

The Global Pulsed Field Ablation Market was valued at USD 1.7 billion in 2024 and is estimated to grow at a CAGR of 24.3% to reach USD 15.9 billion by 2034. The market is primarily driven by the increasing prevalence of cardiac arrhythmias, particularly atrial fibrillation, alongside the rising demand for minimally invasive procedures that offer shorter recovery times and fewer complications compared to traditional thermal ablation methods. Pulsed-field ablation utilizes high-voltage electrical pulses to create irreversible electroporation (IRE), which leads to cell death and tissue scarring. The technique's non-thermal nature offers a significant advantage over heat-based methods, as it minimizes damage to surrounding tissues, making it more appealing for both practitioners and patients.

The growing integration of robotic-assisted pulsed field ablation (PFA) procedures, coupled with the use of advanced imaging technologies, is significantly elevating the precision and efficiency of ablation treatments. Robotic assistance allows for greater control and accuracy during PFA procedures, enabling electrophysiologists to target specific areas of the heart with minimal disruption to surrounding tissues. This precision is particularly beneficial for patients with complex arrhythmias, where traditional methods might present higher risks or lower success rates. Moreover, robotic systems reduce the physical strain on healthcare professionals, improving their ability to perform procedures over extended periods with enhanced comfort.

The catheters segment generated USD 569.1 million in 2024, making it a dominant player in the pulsed-field ablation (PFA) market. These catheters are specifically engineered to deliver high-voltage electrical pulses to target tissues, enabling precise tissue ablation with minimal damage to surrounding areas. As disposable consumables, these catheters are crucial to the continued functionality and growth of the PFA industry, ensuring that they are regularly replaced and replenished, particularly in high-volume electrophysiology centers and hospitals. The ability of these catheters to improve both the safety and effectiveness of PFA procedures has contributed significantly to their demand and adoption in clinical practice.

The hospitals segment accounted for a 44.1% share in 2024. This dominance is largely due to the high frequency of cardiac surgeries performed in hospitals, where advanced surgical infrastructure and well-trained medical teams are available. Hospitals have long been at the forefront of utilizing innovative medical technologies, including PFA, to treat patients with complex arrhythmias. Their ability to conduct intricate procedures and provide post-operative care makes them key players in the PFA landscape, ensuring widespread adoption of this technique. With the increasing patient volume and advancements in surgical techniques, hospitals are expected to remain a major contributor to the market's growth.

Europe Pulsed Field Ablation Market was valued at USD 792.4 million in 2024. Europe's progress is fueled by the active participation of numerous academic institutions and specialized cardiac centers in pivotal clinical research, which has accelerated the adoption of PFA technologies. The region benefits from robust regulatory support, including streamlined approval processes, which allow new technologies like PFA catheters and generators to reach healthcare providers more quickly. Additionally, Europe's focus on minimally invasive electrophysiological techniques is expanding the adoption of PFA, particularly as it aligns with growing trends toward less invasive, highly precise treatments for arrhythmias.

Key players in the Global Pulsed Field Ablation Industry include Abbott, Boston Scientific, CARDIOFOCUS, Johnson & Johnson, and Medtronic. Companies in the pulsed-field ablation market are focusing on enhancing their product portfolios by introducing advanced PFA catheters and generators, while also working on improving the overall safety and efficacy of their devices. These players are investing in clinical trials and research to prove the benefits of PFA technology over conventional treatments. Collaborations with hospitals and academic institutions are key strategies, as they facilitate the adoption of innovative technologies. Additionally, regulatory approvals, such as CE marking in Europe, have expedited the market entry of new products, enhancing global reach.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/Country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis
• 2.2 Key market trends
  • 2.2.1 Regional
  • 2.2.2 Product type
  • 2.2.3 End use

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of atrial fibrillation
    • 3.2.1.2 Growing demand for minimally invasive surgical procedures
    • 3.2.1.3 Advancements in PFA technology
    • 3.2.1.4 Faster procedure times and reduced complications compared to thermal ablation
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Limited availability of skilled electrophysiologists
  • 3.2.3 Market opportunities
    • 3.2.3.1 Integration of PFA with advanced mapping and navigation systems
    • 3.2.3.2 Expansion into emerging markets with high unmet need for arrhythmia treatment
• 3.3 Growth potential analysis
• 3.4 Reimbursement scenarios
• 3.5 Regulatory landscape
  • 3.5.1 U.S.
  • 3.5.2 Europe
• 3.6 Technology and innovation landscape
  • 3.6.1 Current technological trends
  • 3.6.2 Emerging technologies
• 3.7 Gap analysis
• 3.8 Porter's analysis
• 3.9 PESTEL analysis
• 3.10 Value chain analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
  • 4.3.1 By region
    • 4.3.1.1 Global
    • 4.3.1.2 U.S.
    • 4.3.1.3 Europe
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Mergers & acquisitions
  • 4.6.2 Partnerships & collaborations
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Generators
• 5.3 Catheters
• 5.4 Accessory devices

Chapter 6 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Hospitals
• 6.3 Cardiac catheterization labs
• 6.4 Ambulatory surgical centers
• 6.5 Other end use

Chapter 7 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 U.S.
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 UK
  • 7.3.3 France
  • 7.3.4 Spain
  • 7.3.5 Italy
• 7.4 RoW

Chapter 8 Company Profiles

• 8.1 Abbott
• 8.2 Boston Scientific
• 8.3 CARDIOFOCUS
• 8.4 Johnson & Johnson
• 8.5 Medtronic